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Abstract 
 
Accumulating evidence suggests that constitutively active Nrf2 has a pivotal role in cancer as it 
induces pro-survival genes that promote cancer cell proliferation and chemoresistance. The 
mechanisms of Nrf2 dysregulation and functions in cancer have not been fully characterized. Here, 
we jointly analyzed the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) and the Cancer 
Genome Atlas (TCGA) multi-omics data in order to identify cancer types where Nrf2 activation is 
present. We found that Nrf2 is hyperactivated in a subset of glioblastoma (GBM) patients, whose 
tumors display a mesenchymal subtype, and uncover several different mechanisms contributing to 
increased Nrf2 activity. Importantly, we identified a positive feedback loop between SQSTM1/p62 
and Nrf2 as a mechanism for activation of the Nrf2 pathway. We also show that autophagy and 
serine/threonine signaling regulates p62 mediated Keap1 degradation. Our results in glioma cell 
lines indicate that both Nrf2 and p62 promote proliferation, invasion and mesenchymal transition. 
Finally, Nrf2 activity was associated with decreased progression free survival in TCGA GBM patient 
samples, suggesting that treatments have limited efficacy if this transcription factor is overactivated. 
Overall, our findings place Nrf2 and p62 as the key components of the mesenchymal subtype 
network, with implications to tumorigenesis and treatment resistance. Thus, Nrf2 activation could be 
used as a surrogate prognostic marker in mesenchymal subtype GBMs. Furthermore, strategies 
aiming at either inhibiting Nrf2 or exploiting Nrf2 hyperactivity for targeted gene therapy may provide 
novel treatment options for this subset of GBM. 
  
Introduction 
 
The Kelch-like ECH-associated protein 1 (KEAP1/Keap1) – Nuclear factor E2 related factor 2 
(NFE2L2/Nrf2) pathway is the major regulator of cellular defense against endogenous and 
environmental oxidative and electrophilic stress. In basal conditions, Nrf2 is located in the cytosol 
and is bound to the inhibitory Keap1 protein, which facilitates the proteasomal degradation of Nrf2 
via the Cullin3 (Cul3) –based E3 ubiquitin ligase complex. Upon activation by oxidative or 
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electrophilic stress, critical thiol residues in Keap1 are modified rendering it unable to function as a 
substrate adaptor for the E3 ligase, which leads to Nrf2 stabilization and the consequential increased 
activity. Transcriptional induction of Nrf2 target genes provides resistance against endogenous and 
exogenous cytotoxic stresses 1,2. In addition to Keap1-dependent regulation of Nrf2, various 
alternative Keap1-independent mechanisms contribute to the regulation of Nrf2. These include the 
binding of disruptor protein p62 3,4 on Keap1, which inhibits the interaction of Nrf2 and Keap1 causing 
an increase in cellular Nrf2 protein and its activity.    
  
It has become evident that malignant cells benefit from having increased Nrf2 pathway activity. This 
was first observed in lung cancer 5,6, as well as subsequently in many other cancer types, such as 
pancreatic, ovarian, liver and gallbladder cancers 7–9. Aberrant Keap1-Nrf2 signaling leads to radio- 
and chemoresistance and provides growth advantage to cancer cells, due to constitutive expression 
of cytoprotective genes 2,9,10. Multiple mechanisms for Nrf2 overactivation have been found, such as 
somatic mutations in either KEAP1 or NFE2L2, deletion of exon 2 of NFE2L2, aberrant expression 
of inhibitory proteins and transcriptional induction by oncogenes and hormones 2,11.  
 
Glioma is a type of tumor in the brain originating from malignant glial cells. Gliomas are classified to 
WHO grades I-IV by cell type, morphology and mutations. Low-grade gliomas are grade I-II and are 
well-differentiated whereas high grade gliomas are grade III-IV and are undifferentiated. GBM is a 
grade IV tumor and is the most common form of brain cancer among adults, and has an extremely 
poor prognosis, the median survival from diagnosis being only 15 months12. GBM is classified into 
five subtypes: mesenchymal, classical, proneural, neural and G-CIMP, based on the gene 
expression, DNA methylation and mutation patterns that they possess 13–15. The mesenchymal 
subtype is characterized by the expression of mesenchymal and angiogenic genes and is highly 
invasive. Retaining mesenchymal properties have been proposed to be crucial for the survival of 
cancer cells, as stem cell-like cells are resistant to treatment and promote tumor regrowth and 
relapse 16. 
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In this study, we developed and benchmarked Nrf2 activation signature, based on gene expression 
profiles, and utilized it to identify cancer types with overactive Nrf2 pathway across 915 samples in 
the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) 17. In addition to cancer cell types having 
a previously well-established Nrf2 overactivity profile, we found that Nrf2 is also hyperactive in cancer 
cells of glial origin. We confirmed this in glioma patient samples available from independent studies, 
namely the Rembrandt, the Cancer Genome Atlas (TCGA) GBM study 18 and the Human Glioma 
Cell Cultures (HGCC) collection 19. In addition, we interrogated the mechanisms behind Nrf2 
hyperactivity and the functional role of this transcription factor in glioma. 
  
Results 
 
Benchmark of Nrf2 activity inference methods 
We combined data from adenoviral overexpression of Nrf2 for 36 and 72 h and short term treatment 
with the Nrf2 activator nitro-oleic acid (OA-NO2) in HUVEC to form a group with activated Nrf2 20 and 
compared this group against  samples with basal Nrf2 activation state. We tested a probit regression 
model 21 to infer Nrf2 activation using a supervised approach using the different Nrf2 activation states 
as training data. NFE2L2 and KEAP1 mutations are the predominant mechanism that disrupts the 
Keap1-Nrf2 interaction (causing Nrf2 overactivity) in lung squamous (LUSC) and adenocarcinomas 
(LUAD) as well as the head-and-neck squamous carcinoma (HNSC), making these cancer types the 
ideal benchmarking sample sets for which the prediction outcome (Nrf2 activity) can be estimated 
from mutation data. The Receiver-Operator-Curve (ROC) analysis (Fig. S1A) shows that high Nrf2 
activity score (> 80% probability) obtained with the regression model recovers mutated samples with 
high specificity and sensitivity (81, 76 and 79% sensitivity with 88, 86 and 80% specificity in LUAD, 
HNSC and LUSC, respectively). Additionally, we tested a gene set-based approach using several 
existing Nrf2 gene sets and different enrichment methods. The NFE2L2.V2 and 
BIOCARTA_ARENRF2_PATHWAY gene sets included in MsigDB had poor performance (data not 
shown). However, SINGH_NFE2L2_TARGETS pathway and GSVA tool were good predictors of 
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Nrf2 activation (Fig. S1B-D). Therefore, Nrf2 activation could be inferred using both supervised and 
unsupervised gene set-based methods from patient data. 
 
Nrf2 activity prediction across a panel of cancer cell lines 
We applied the regression model to identify cell lines displaying Nrf2 overactivity, from CCLE sample 
collection which contains gene expression profiles from 915 cell lines representing 36 cancer types 
(Fig. 1A-B, Table S1). GSVA resulted in a highly similar prediction, as 90% of the cell lines predicted 
by our approach were significantly enriched (FDR<0.05). We defined 5 Nrf2 activity categories based 
on the transcription factor (TF) activity probability, as shown in Fig. 1C. In 66 cell lines (constituting 
about 7% of all cell lines) representing 12 cancer types our analysis predicted to have an over 95% 
probability of overactive Nrf2. Using a less stringent cutoff of > 80% probability, we identified a total 
of 174 cell lines (approximately 19% of cell lines examined) (Fig. 1D). The predicted activity in kidney, 
esophagus, liver and lung cancers was in agreement with previous studies, where mutations of either 
Nrf2 or KEAP1 have been detected 6,22–24. Nrf2 activity was high also in 10.6% of the glioma cell 
lines. Since the mechanisms of Nrf2 dysregulation in glioma remained ill understood, we were 
motivated to further analyze the role of Nrf2 activity in glioma. 
 
Nrf2 is constitutively activated in glioma cell lines and GBM patient samples 
First, we determined how glioma WHO grade I-IV correlates to Nrf2 overactivity using 550 patient 
microarray gene expression profiles from the Rembrandt dataset. Interestingly, Nrf2 activity was 
gradually higher in grades II-IV, whereas in grade I none of the patient samples had high Nrf2 activity 
(Fig. 1E). As a confirmation, Nrf2 activity was inferred using RNAseq data from 166 grade IV TCGA 
GBM samples. Similarly to the Rembrandt grade IV tumors where Nrf2 activity was high in 13% of 
the samples, 17% of the samples had high Nrf2 activity in TCGA GBM samples and the highest 
activity with P>95% was detected in 4% in TCGA and 1.6% in the Rembrandt datasets (Fig. 1D). 
We confirmed that the Nrf2 activity marker genes correlate with Nrf2 activity (Fig. 2A-B). Similarly, 
patient derived xenograft HGCC 48 cell lines were used to verify Nrf2 activity in GBM cell lines using 
GSVA (Fig. S1). 
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As an experimental confirmation of the predicted Nrf2 hyperactivity, we chose three glioma cell lines 
with > 95% probabilities (H4, T98G and GAMG, referred to as Set 1) and four glioma cell lines with 
> 80% probabilities of above average Nrf2 activity (LN18, A172, U87 and U251, Set 2) for 
experimental verification of Nrf2 activity status. Immortalized normal human astrocyte cells (NHA-
cells) and a glioma cell line with a predicted low Nrf2 activity (DKMG) were chosen as negative 
controls, whilst the A549 lung adenocarcinoma cells with known Nrf2 hyperactivity6 served as a 
positive control. First, we evaluated the level of Nrf2 activity using the luciferase reporter assay with 
a lentiviral luciferase reporter construct under the control of minimal SV40 promoter and four Nrf2 
binding sites (AREs) derived from the human GCLM 25. Robustly elevated activity was found in A549 
and Set 1 cell lines compared to NHA cells, and slightly increased activity in 2 of 4 (LN18 and A172) 
Set 2 cell lines (Fig. 2C). Next, Nrf2 target levels were analyzed by western blotting (Fig. 2D) and 
RT-qPCR (Fig. S2). GCLM, NQO1 and HMOX1 proteins were increased in all Set 1 glioma cell lines, 
with a more variable pattern in Set 2. Moreover, the binding of Nrf2 on ARE on NQO1 and HMOX1 
promoters was studied using chromatin immunoprecipitation (ChIP) in T98G, GAMG and DKMG 
cells. The binding of Nrf2 on NQO1 and HMOX1 ARE was significantly increased in T98G and 
GAMG cells compared to DKMG (Fig. 2E). In summary, the cell lines with > 95% probability (H4, 
T98G and GAMG cells) each showed evidence of overactivated Nrf2 pathway, whereas cell lines 
selected for validation from Set 2 (displaying lower probability thresholds) had high Nrf2 activity in 2 
out of the 4 cell lines examined (LN18, A172) on reporter assay. However, these cell lines had more 
variable patterns of target gene expression. 
 
Nrf2 activity is linked to Nrf2 and Keap1 gene expression imbalance 
As the percentage of Nrf2 overactive samples was the highest in grade IV tumors, we next 
investigated the potential mechanisms of activation in GBM using multi-level TCGA patient data and 
cell lines from CCLE and HGCC. GBM samples lacked mutations in NFE2L2 and KEAP1 in TCGA 
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patient data. We obtained similar results when glioma cell lines T98G, GAMG, LN18, DKMG and 
NHA control cells were sequenced (data not shown). 
 
NFE2L2 and KEAP1 mRNA expression showed a negative relationship in TCGA and HGCC data 
and in H4 and T98G cell lines (Fig. 3 A-B, Fig. S3). KEAP1 copy-number gain was associated with 
concomitant increase in its mRNA and Nrf2 inactivity, whilst KEAP1 expression was significantly 
lower in patients representing Nrf2 overactive samples and not attributed to differential methylation 
(data not shown). We found a deletion of KEAP1 in H4 cell line and amplification of NFE2L2 in T98G 
and to validate the effect on gene expression, we performed RT-qPCR for NFE2L2 and KEAP1. We 
found highly elevated expression of NFE2L2 in T98G cell line, but KEAP1 mRNA was significantly 
decreased only in LN18 and significantly upregulated in A172 (Fig. 3C-D). We also compared the 
protein levels relative to control cell lines with western blotting. Nrf2 was over-expressed in all Set 1 
and in one Set 2 cell lines, (Fig. 3E, in H4, T98G, GAMG and LN18). Moreover, H4 and LN18 showed 
decreased Keap1 protein, whereas in T98G and GAMG Keap1 protein was approximately at the 
same level or increased compared to controls (Fig. 3F). Taken together, the observed Nrf2 
hyperactivity could be linked to expression imbalance of NFE2L2 and KEAP1 within the patient 
cohorts, which was also evident in cell line models. 
 
Pathway analysis reveals central cancer processes correlated to Nrf2 activity 
We performed enrichment analysis of oncogenic signatures and biological pathways using GSEA to 
identify processes linked to Nrf2 activity. Significant pathways (FDR<0.05) from TCGA, CCLE and 
HGCC datasets were linked to larger biological processes and ranked based on their mean 
enrichment score (Fig. 4A). The highest ranked cancer-related process was mesenchymal transition, 
suggesting that increased Nrf2 activity could be linked to the mesenchymal subtype, or contribute to 
mesenchymal transition. Proliferation was linked to Nrf2 activity through cell cycle and energy 
metabolism. Importantly, our analysis also associated invasion with Nrf2 activity, together with redox 
and other stress responses that could be clinically relevant in drug resistance. Several pathways 
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were also linked to proteasomal degradation and autophagy. We hypothesize that these processes 
could contribute to Nrf2 activation or function as key Nrf2 regulated pathways in GBM.  
 
Autophagy dysregulation is linked to Nrf2 activation 
To further investigate the link between autophagy and Nrf2 overactive cells, we examined the 
expression of the autophagy-related protein, microtubule-associated protein light chain 3 (LC3) (Fig. 
4B). Two bands of LC3 can be separated in Western blots, the upper migrating band (LC3-I) 
representing cytosolic LC3 and the lower migrating band (LC3-II) is present in isolated membranes 
and autophagosomes 26. In addition, the treatment of cells with Bafilomycin A (BafA), which inhibits 
the fusion of autophagosome with lysosomes 27, was together with the LC3 Western blot used for 
evaluating whether autophagy was functional. The protein level of LC3-II was accumulated in basal 
conditions in GAMG and U-87 MG cells. In all cell lines, except for GAMG, there was an increase in 
LC3-II in response to BafA (Fig. 4B), indicating functional autophagy. We also analyzed H4, T98G, 
GAMG, LN18 and NHA cells with transmission electron microscopy to confirm the presence of 
autophagosomal structures (Fig. 4C). In agreement with the LC3-II data, we found that 
autophagosomal and autolysosomal structures were abundant in GAMG and T98G cells, but not in 
LN18 or NHA cells. In addition, in GAMG cells, a high number of dark amorphous 
endosomal/lysosomal-like structures were present, which in combination with the LC3 Western blot 
results indicates that the autophagosomal pathway is dysfunctional in GAMG cells. 
      
The SQSTM1/p62 and Nrf2 positive feedback loop regulates Nrf2 activity in glioma 
Sequestosome1 (SQSTM1/p62) is a stress-inducible and multifunctional protein, that selectively 
targets proteins for autophagy and ubiquitin degradation 28. It has been previously reported that in 
HCC mTOR activated p62 can bind to Keap1 and promote autophagosomal degradation of Keap1, 
leading to constitutive activation of Nrf2 4,24,29. We observed increased p62 protein and SQSTM1 
mRNA levels in Nrf2 overactive cell lines H4, T98G and GAMG but also in A172 and U-87 MG cell 
lines (Fig. 5 A-B). Strong significant correlation between SQSTM1 and Nrf2 activity was observed in 
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all datasets (GBM shown in Fig. 5C). We also noted strong correlation (FDR = 0.000024) between 
the protein levels of p62 and Nrf2 activity in 82 TCGA GBM Reverse phase protein lysate microarray 
(RPPA) patient samples (Fig. 5 D). To compare Nrf2 and p62 association strength to other diseases, 
we performed a correlation analysis between Nrf2 GSVA score and SQSTM1/p62 expression within 
33 cancer types included in the TCGA cohorts. The correlation between Nrf2 activity and 
SQSTM1/p62 was particularly strong in GBM and in Kidney renal papillary cell carcinoma (KIRP), 
whereas the correlation was poor in frequently Nrf2 overactive HNSC, suggesting that the p62-
dependent Nrf2 regulation is important in select cancers (Fig. 5 E). Based on the genetic information, 
elevated SQSTM1 mRNA in A172 is likely due to SQSTM1 amplification (Fig. 5 E). Given that 
SQSTM1 has been shown to be also transcriptionally regulated by Nrf230, we confirmed, using RT-
qPCR, that the expression of NFE2L2 and its target genes were significantly reduced by Nrf2 and 
p62 siRNA knockdown in these cells and SQSTM1 gene expression was reduced by Nrf2 
knockdown in T98G cells (Fig. S4).  
      
Next, we used co-immunoprecipitation to determine whether Keap1 and p62 are bound to each other 
in T98G and GAMG cells having upregulated Keap1-Nrf2 pathway, and in A172 in which Nrf2 activity 
is normal but p62 is upregulated. We found that these proteins interact with each other in all three 
cell lines, further supporting the importance of p62 in Keap1 protein turnover (Fig. 5G). Moreover, 
as the Ser-351 phosphorylation of p62 has been shown to increase the binding affinity between 
Keap1 and p6229, we also studied the Ser-351 phosphorylation of p62 in all glioma cell lines and 
found a clear Ser-351 and Ser-403 phosphorylation of p62 in T98G (Fig. 5H). We also studied co-
localization of p62 and Keap1 by confocal immunofluorescence analysis. T98G cells contained a 
high number of large p62-Keap1 aggregates, whereas in other cell lines co-localization was less 
evident (Fig. 5I, Fig. S5). 
      
Nrf2 and p62 jointly regulate mesenchymal transition in the mesenchymal subtype of GBM 
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Mesenchymal transition was ranked as one of the top significantly affected pathways (Fig. 4A). 
Therefore, we examined the prevalence of Nrf2 overactivity in different molecular subtypes of GBM. 
Our analysis revealed that Nrf2 activity correlated with samples assigned to the mesenchymal 
subtype, accounting for 83% of Nrf2 active samples in TCGA data (Nrf2 highest, Fig. 6A). All HGCC 
samples with high Nrf2 activity were of mesenchymal subtype (Fig. S6A). Nrf2 activity anti-correlated 
with the classical subtype, suggesting that there could be a link between Nrf2 activity and pathway 
profiles of mesenchymal and classical subtypes. In comparison to the mutation data (Fig. 2), Keap1 
copy-number gain (associated with Nrf2 inactivity) was also correlated with the classical subtype. 
NF1 is typically mutated in mesenchymal subtype14, but not in Nrf2 overactive samples (Fig. S6B). 
We correlated also TCGA protein array data to Nrf2 activity and identified that the expression of 
endothelial VEGFR2 and PECAM1 and cell adhesion molecule P-Cadherin is significantly 
correlated, whereas NOTCH1 and EGFR expression significantly anticorrelated with Nrf2 activity 
(Fig. S7). 
 
To compare Nrf2 and mesenchymal transition association to other diseases, we performed a 
correlation analysis between Nrf2 GSVA score and epithelial to mesenchymal transition (EMT) 
associated gene sets within 33 cancer types included in the TCGA cohorts. Correlation between 
Nrf2 activity and EMT was particularly strong in GBM and LGG, whereas EMT was significantly 
anticorrelated to Nrf2 activity in HNSC and LUSC, suggesting that the Nrf2 activity correlation to 
EMT is context dependent and highly specific to gliomas (Fig. 5 E). 
 
We then analyzed whether the mesenchymal phenotype, as defined by mesenchymal markers such 
as SNAI1/Snail, SNAI2/Slug, CTNNB1/ß-catenin and VIM/Vim, are linked to Nrf2 and p62 
expression. In both the GAMG and T98G cell lines, Nrf2 and p62 siRNA knockdown resulted in a 
significant reduction of both the mRNA and protein levels of these markers (Fig. 6C, Fig. S6C-D).      
We used MAF, BACH1 and Nrf2 ChIP-seq data from the Encyclopedia of DNA Elements at UCSC 
(ENCODE 3) together with U87 and T98G Global run on sequencing (GRO-seq) data from31 for 
finding putative ARE containing enhancer for the mesenchymal markers.  We identified putative Nrf2 
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binding sites in the proximal enhancer regions of SNAI2 and CTNNB1 (Fig. S8). The binding of Nrf2 
to these regions was significantly higher in Nrf2 active T98G and GAMG cells compared to DKMG 
with low Nrf2 activity, assessed by ChIP-PCR (Fig. 6D). Taken together, Nrf2 is involved in EMT 
regulation in glioma and directly regulates SLUG and ß-catenin expression. 
 
Nrf2 overactivity affects progression free survival in GBM patient samples and increases cell 
proliferation and invasion in glioma cell lines 
Next, we analyzed TCGA GBM prognostic clinical data stratified by the Nrf2 activity status. We 
merged Nrf2 overactive and low activity samples from TCGA microarray and RNAseq data to 
increase the cohort size to 520 cases. We found no difference in the overall survival of Nrf2 active 
patient samples. However, patients with the highest Nrf2 activity (22/520) were strongly associated 
with decreased progression free survival (likelihood ratio test 0.0022, HR 2.6) (Fig. 7A). Multivariate 
analysis using the RNAseq samples of Nrf2 activity probability and glioblastoma subtypes revealed 
that Nrf2 activity probability is significantly linked to progression also when considering the disease 
subtypes (Fig. S9A). We also considered other prognostic factors, such as age, gender, IDH 
mutation status, recurrence, MGMT methylation status and subtype together with Nrf2 activation 
categories. The highest Nrf2 activity remained a significant predictor of faster disease progression 
(Likelihood ratio test, overall model p-value 1e-8, Nrf2 Highest category p-value 0.0013) (Fig. S9B). 
      
The pathway analysis associated Nrf2 activity with proliferation and invasion (Fig. 4A and Table S2). 
We found significant positive correlation to G6PD protein expression (Fig. S7), a known promoter of 
cellular proliferation. Accordingly, Nrf2 and p62 siRNA knockdown in GAMG and T98G cells resulted 
in a significant decrease in cell proliferation at 24 to 96 h, with the most pronounced reduction 
observed at the 24 h time point (Fig. 7B). T98G cells were able to invade into 3-dimensional type I 
collagen-cultrex matrix, as judged by actin cytoskeleton and cellular nuclei staining. Upon Nrf2 and 
p62 siRNA knockdown, cell invasion was significantly impaired (Fig. 7C). Next, we analyzed 
anchorage-independent growth in GAMG and T98G cells by growing the cells in ultra-low attachment 
plates. Both cell lines formed 3-dimensional spheres in serum-free growth conditions (Fig. 7D and 
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Fig S10). In conditions of Nrf2 and p62 siRNA knockdown, the growth of these spheres was 
significantly inhibited (Fig. 7D and Fig. S10). Results were confirmed using different siRNAs (Fig. 
S11). 
Discussion 
 
In this study, we show that Nrf2 pathway is overactive in a subset of glioma, mainly in GBM 
mesenchymal subtype. Furthermore, p62 creates a positive feedback loop with Nrf2 in glioma, 
capable of promoting tumorigenesis and stemness properties, as summarized in Fig 7E. 
 
Nrf2 overactivity was prevalent in the mesenchymal subtype, which could be explained by the ability 
of Nrf2 and p62 to promote stem cell markers associated with this subtype. Interestingly, 
mesenchymal subtype had higher Nrf2 expression and lower Keap1 expression, suggesting that 
Nrf2 upstream regulation promotes increased Nrf2 activity in the mesenchymal subtype. On the 
contrary, Nrf2 inactivity correlated with the classical subtype, with gene expression imbalance 
favoring low Nrf2 activity and high NOTCH and EGFR levels. 
 
Autophagy and lysosomal pathways and serine/threonine signaling correlated with Nrf2 activity both 
in cell lines and in patients. Autophagosomal and autolysosomal structures were found in glioma cell 
lines, but autophagosomal pathway was defective only in GAMG cells. Thus, in GAMG cells, due to 
defects in autophagy, p62 accumulates, binds to Keap1 resulting in Nrf2 release and observed 
hyperactivity (Fig. 5G). Interestingly, Nrf2 also regulates several autophagy genes in addition to 
SQSTM132, which is likely to impact the strength of the Nrf2 and p62 feedback and contribute to 
autophagy dysregulation. In comparison, in T98G cells autophagy was intact, whereas increased 
p62 -Keap1 interaction could be attributed to p62 Ser-351 and Ser-403 phosphorylation. Nrf2 and 
p62 dependency on mTOR signaling has been reported in lung cancer33. Furthermore, 
RTK/RAS/PI3K is altered in 88% of glioma patients and drives growth in GBM18. Increased activation 
of the MAPK pathway with increased phosphorylated RAF/MEK/ERK has also been reported in 
GBM, especially in the mesenchymal subtype18. Similarly, we found significant positive correlation 
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between Nrf2 activity and phosphorylated A-RAF and MEK expression (Fig. S7). Therefore, several 
kinases could influence Nrf2 activity, but functional redundancy in signaling networks and their 
connectivity to p62 may explain why Nrf2 activity may arise via alternative mechanisms in GBM. 
Taken together, both autophagy dysregulation and constitutive serine/threonine signaling targeting 
of Ser-351 and Ser-403 are likely to promote Nrf2 overactivation through p62 in glioma. 
 
A previous study of 10 GBM and 95 anaplastic glioma samples34 indicated that p62 accumulation is 
not linked to Nrf2 overactivation. Instead, IDH1 gene mutations were shown to affect Nrf2 activity in 
anaplastic glioma, but not in GBM. Accordingly, Nrf2 target genes were shown to correlate with poor 
prognosis in anaplastic glioma but not in GBM. The different conclusions regarding p62 correlation 
to Nrf2 activity in GBM may be due to differences in cohort sizes. We have shown in CCLE, TCGA 
and HGCC data sets that correlation between p62 and Nrf2 exists, and validated the dependency 
between Nrf2 and p62 expression levels. Furthermore, mutations in the IDH1 gene are not correlated 
to Nrf2 activity in our analysis of GBM, confirming previous findings34. 
 
Our results demonstrate that in GBM cells, inhibition of Nrf2 and p62 decreased tumorigenic 
properties, such as cell invasion and anchorage-independent growth. This could be partially 
explained by the fact that mesenchymal proteins such as Snail, Slug, vimentin and beta-catenin are 
reduced upon siRNA knockdown of Nrf2 and p62. High expression of autophagy regulators including 
p62 and increased MAPK pathway activation have been previously associated with aggressive 
properties in mesenchymal subtype of GBM35. p38-MAPK and Nrf2 pathway activation in response 
to ROS has been previously shown to increase glioma survival and promote glioma reprogramming 
towards the mesenchymal phenotype36. In line with these findings, our discovery of Nrf2-p62 joint 
contribution in promoting mesenchymal properties could reveal how GBM mesenchymal subtype 
acquire an aggressive phenotype that is resistant to treatments. 
 
On a functional level, our data shows that inhibition of Nrf2 and p62 resulted in defective proliferation 
in GBM cells, supporting the idea that Nrf2 is involved in metabolic rearrangements to support 
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proliferation. Metabolic reprogramming is a major hallmark in glioma, which is characterized by 
upregulated glycolysis, PPP (pentose phosphate pathway) and lipid metabolism, among others37. 
Activation of these metabolic pathways provides molecular building blocks for the high anabolic 
demands of cancer cells. PPP activation is also an important source for NADPH generation, which 
is required for antioxidant generation and in anabolic pathways as a reducing agent38. Key metabolic 
genes, such as G6PD, PGD, TALDO1 and ME1 are direct targets of Nrf2 and direct flux from 
glycolysis to PPP 39. Our analysis revealed a high correlation between G6PD expression and Nrf2 
activity, confirming previous findings. Nrf2 could also function as a key balancing factor in metabolic 
reprogramming, as Nrf2 is capable of regulating both energy metabolism and antioxidant response 
to ROS to favor glioma growth and development. Cancer cells tolerate moderate oxidative stress 
and increased ROS levels contribute to proliferation, genetic instability and evasion from senescence 
40. However, excessive ROS exposure causes oxidative damage and apoptosis41,42. The ability of 
Nrf2 to simultaneously produce NADPH through increased PPP flux to prevent excess oxidative 
damage could be a crucial protective mechanism. Consequently, the ability of Nrf2 to regulate 
enzymes involved in the detoxification of drugs would support radio- and chemotherapy resistance 
in gliomas harboring overactivity of this transcription factor. In line with this, we have shown that 
patients with the highest Nrf2 activity have decreased progression free survival in TCGA cohort, 
suggesting that treatments have limited efficacy in these patients. Also, Nrf2 activity increased 
gradually in glioma grades II-IV.  Therefore, to fully assess the extent of Nrf2 activity and its clinical 
impact, it would be important to study Nrf2 activity in relapsed GBM samples and during treatment. 
 
Nrf2 pathway has been widely studied using multi-omics cancer datasets11,43,44. However, these 
studies are limited to samples with mutations in either the NFE2L2 or KEAP1. In this study, we 
performed computational predictions of Nrf2 activity in cell line and patient samples, using Nrf2 target 
gene signatures. This approach could be widely applied to study oncogene activation mechanisms 
and downstream effects using multi-omics data sets, such as TCGA and CCLE. Our approach has 
power especially in cancers that have no somatic mutations in the Keap1-Nrf2 pathway components 
such as GBM and enable investigation of indirect mechanisms of Nrf2 activation. 
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The discovery of Nrf2 and p62 as key components of the mesenchymal subtype molecular network 
as well as the evident role of Nrf2 in metabolic reprogramming will facilitate new discoveries in 
understanding how GBM acquires treatment resistance and invasive phenotype. 
 
Materials and Methods 
Reagents 
All reagent full names and abbreviations, company, city and country are listed in Table S3. 
 
Cell lines and culture conditions 
Human endothelial cells (HUVEC) were isolated and grown as described previously 45. Human GBM 
cell lines U87, U251, H4, LN18, A172 and lung carcinoma cell line A549 were cultured in DMEM 
supplemented with 10% (v/v) FBS and 1% penicillin/streptomycin. T98G cells were cultured in MEM 
supplemented with 10% FBS, 2 mM L-glutamine, 4x MEM nonessential amino acids and 1% 
penicillin/streptomycin, DKMG were cultured in RPMI-1640 medium supplemented with 10% FBS, 
2mM L-glutamine and 1% penicillin/streptomycin; and NHA cells were grown in DMEM 
supplemented with 10% FBS, 2mM L-glutamine, 50mg/ml hygromycin and 1% 
penicillin/streptomycin.  
 
Microarray analysis to define an activity signature for Nrf2 
Microarray profiling was performed from adenoviral overexpression of Nrf2 in HUVECs pooled from 
three separate donors for 36 and 72 h using the Affymetrix U133 plus 2.0 platform. For the analysis, 
cells were transfected with CMV-promoter-Nrf2 or CMV-promoter-only containing adenoviral 
expression vectors using multiplicities of infection (MOI) 50. Triplicate samples were used. Sample 
collection and microarray analysis were performed as in 45. Raw data files were normalized using 
GC-RMA and gene level expression values were obtained using Brainarray probe mapping. These 
results and microarray data from 45 consisting of transient activation by nitro-oleic acid (OA-NO2) 
were combined for identifying an Nrf2 dependent gene signature. The Nrf2 negative training set 
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contained adeno-CMV transduced, or solvent and oleic acid (OA) treated samples from the two 
experiments, respectively.  
 
Datasets 
CCLE data was downloaded from Gene expression Omnibus (GEO, series GSE36133) to infer Nrf2 
activity across various cancer types. Copy number results were downloaded from CCLE data portal 
(Nov 2014). Level 3 TCGA data was downloaded from TCGA data portal and clinical and sample 
annotation and subtype data was obtained from the publication supplementary table 718. Processed 
HGCC gene expression and sample annotation data was downloaded from http://www.hgcc.se/. 
Copy number values for each DNA segment were downloaded using id GSE72209. The Rembrandt 
study gene expression profiles and clinical data were downloaded using the GEO database 
(GSE108474) and normalized using RMA and gene expression values obtained using Brainarray 
probe mapping. TCGA GBM Affymetrix U133 plus 2.0 platform samples processed data matrix was 
downloaded from http://gliovis.bioinfo.cnio.es46. Pan-Cancer Atlas containing RNAseq and RPPA 
profiles for TCGA 33 diseases were downloaded (June 2019) from https://gdc.cancer.gov/about-
data/publications/pancanatlas. U87 and T98G GRO-seq bedGraph files were downloaded from 
GSE92375. 
 
Predicting Nrf2 activity in cancer data sets 
Using the compiled microarray data, the command line version of Binreg2 algorithm and 
SIGNATURE tool 21 were used to distinguish samples with high probability of Nrf2 activity (Table S1). 
The gene set variation analysis (GSVA) 47 available in the R/Bioconductor package GSVA 1.22.4, 
and SINGH_NFE2L2_TARGETS gene set from MsigDB48 were used to assign a Nrf2 gene set 
enrichment score in a sample-wise manner with the following settings: mx.diff=F, tau=0.25, 
rnaseq=F for CCLE, HGCC and TCGA pancan33 datasets. Random gene-set permutations were 
computed to obtain FDR values to estimate significance of the enrichment scores for HGCC data. 
 
ROC analysis comparing Nrf2 activity predictions on a gold standard gene set 
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Gene set variation analysis (GSVA) available as an R/Bioconductor package contains several 
enrichment analysis implementations, including GSVA, ssGSEA and combined Z-score. These tools 
were used to compare available Nrf2 gene sets (SINGH_NFE2L2_TARGETS, NFE2L2.V2, Nrf2 
canonical) to the Bayesian probit regression using the ROCR R package. A gold standard set was 
used for the comparison consisting of sequenced luad, lusc, hnsc samples (n=483, n=178, n=489, 
respectively) with high rate of NFE2L2-KEAP1 missense mutations (77, 45, 43, respectively), that 
are previously described to disrupt the Nrf2-Keap1 interaction and lead to Nrf2 overactivation. 
Mutated samples were considered as true positives and other samples as true negatives. 
 
GSEA 
Gene Set Enrichment Analysis (GSEA) 49 was used to perform pathway analysis. Nrf2 activity was 
used as a continuous phenotype in CCLE, HGCC and TCGA data using a Pearson correlation as 
metric and sample permutation to obtain FDR q-values. For this purpose, gene sets from MsigDB 
v5.0, Wikipathways (06.2015), Recon 1 and Pathway commons 7 were obtained.  
 
Kaplan-Meier survival analysis 
Survival and progression time and status for each TCGA GBM sample was obtained from the 
supplementary table 7 from the publication18. The R package ‘survival’ was used to compute 
univariate and multivariate cox proportional hazard model to test whether Nrf2 activity affects patient 
overall and progression free survival. Kaplan Meier curves were used to visualize differential Nrf2 
activity groups. Proportional Hazards Assumption of a Cox Regression was verified using the 
cox.zph weighted residuals method in R. 
 
RNA isolation and quantitative real-time PCR 
Total RNA was extracted with TRI-reagent. One microgram of the RNA was used for cDNA synthesis 
by Transcriptor First Strand cDNA synthesis kit. The relative expression levels were measured by 
qPCR using relative standard curve method (StepOnePlus Real-Time PCR Systems, Applied 
Biosystems) with specific primers and probes listed in Table S4. 
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Western blotting 
Cells were lysed, and total protein concentration was measured with BCA assay (Pierce). Western 
blotting was performed as previously described 25 with the exception that PVDF membrane was used 
for LC3B detection instead of nitrocellulose membrane. 
 
Luciferase reporter gene assay 
Luciferase reporter gene assays were performed as previously described 25. To test transduction 
efficiency in each cell line, a lentiviral construct expressing GFP under human PGK promoter was 
used 50. MOI yielding >90% of GFP positive cells in FACS analysis were used for transduction. MOI 
values are shown in Table S5. 
  
siRNA transfections 
Cells were transfected with siRNA oligonucleotides targeting NFE2L2 or SQSTM1 gene expression, 
or a non-specific siRNA control (20 nmol/l) using RNAiMax according to manufacturers’ instructions. 
The siRNA sequences used were as follows: siNrf2 (catalog no. s9493 and s9492, Thermo Scientific) 
and sip62 (catalog no. s16960 (Thermo Scientific) and 5´-GCAUUGAAGUUGAUAUCGAUTT-3’ 
(Invitrogen)). Cells were collected at 48 h time point for q-RT-PCR or for Western blotting.  
  
Fluorescence microscopy 
Cells were fixed in 4% paraformadehyde in PBS, permeabilized with 0.2% Triton-X-100 in PBS and 
blocked with FBS prior to incubation with mouse monoclonal p62 antibody and goat polyclonal Keap1 
antibody o/n in +4oC. After washing with PBS, samples were incubated with secondary antibody 
Alexa Fluor® 488 Donkey anti-goat IgG (H+L) and Alexa Fluor® 647 rabbit anti-mouse IgG (H+L) 
for one hour and with DAPI for five minutes. Samples were examined with Olympus FV 1000 and 
Zeiss LSM 700 confocal microscopes. 
  
Transmission electron microscopy 
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Cells were prefixed in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.4), postfixed in 1% 
osmium tetraoxide for 1 hour and dehydrated with ethanol. The samples were infiltrated and 
embedded in Epon LX-112. After polymerization in +60oC for 48 hours, samples were stained with 
1% uranyl acetate and lead citrate. Finally, samples were examined with Jeol JEM-1200EX (80 kV). 
 
Co-immunoprecipitation 
Co-immunoprecipitation of p62 and Keap1 was performed as in 51. 
 
Cell proliferation assay 
GAMG and T98G cells were plated on 6-well plates and treated with siRNAs the following day. Cells 
were then allowed to grow in reduced serum medium (4% FBS containing growth medium) for 24, 
48, 72 and 96 h and counted using a hemocytometer. Results are expressed as cell numbers/ml.   
 
Cell invasion assay in 3D collagen-cultrex matrix 
T98G cells, grown and treated with siRNAs in 6-well plates, were trypsinized after 48 h of treatment 
and plated 60,000 cells/well on 8-well Ibidi chambered 𝝁-slides. 24 h later, the confluent culture of 
cells was coated with a 1:1 mix of of 2.4 mg/ml each of 3D matrix containing type I collagen and 
cultrex for an hour at 37oC, according to manufacturer’s instructions. Later, growth medium was 
added on top of the solidified matrix and the cells were allowed to invade the matrix for 24 h. Later, 
cells were fixed with 4% paraformaldehyde in 0.1M phosphate buffer (PB) for 1.5 h, washed with PB 
several times, permeabilized with 0.1% TritonX-100 in 1% bovine serum albumin (BSA)-PB for 30 
min, blocked with 1% BSA-PB for 40 min, stained with Alexafluor 594-conjugated Phalloidin 
(Molecular Probes) in PB (according to manufacturer’s instructions) for 1.5 h and then with DAPI 
(1𝝁g/ml) for 15 min. The slides were stored at 4oC until use. 20x optical sections with an interval of 
2𝝁m and a range of 55-65 slices were taken in Z direction using a Zeiss LSM 700 confocal 
microscope and the images were stacked to get a 3D projection. Using ImageJ, the mean 
fluorescence of Alexafluor 594-Phalloidin and invasion area of the cells were measured. An average 
of 15 images/group from 3 independent experiments were used. 
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3-dimensional spheroid formation assay 
GAMG and T98G cells, grown and treated with siRNAs in 6-well plates, were trypsinized after 48 h 
of treatment and plated respectively as 1000 cells/well and 2500 cells/well in serum-free growth 
medium in Ultra-low attachment 96-well plates. 6 replicates/group were used in a single experiment. 
Growth of spheres at day 7 was imaged using a 10X objective in a standard light microscope. The 
experiment was repeated five times and the area of spheres was measured using ImageJ program.  
      
Analysis of EMT markers 
The levels of SNAIL, SLUG and ZEB1 mRNA were analyzed by qPCR from three repeats. GAPDH 
expression was used for normalization. Three repeats of western blot analysis were done for 
mesenchymal markers: snail, slug, vimentin and CTNNB1/beta-catenin, with beta-actin and lamin-
B1 used for normalization. 
 
Chromatin Immunoprecipitation 
ChIP was performed as previously described in 52 with following modifications: Prior to 
immunoprecipitations, 20 μl of Magna ChIP magnetic beads (Millipore) per immunoprecipitation were 
re-suspended to 1 ml of PBS/BSA (5 mg/ml). Beads were washed with PBS/BSA and re-suspended 
in 2 ml of PBS/BSA. 5 μg of antibody (Nrf2, sc-722, or anti-rabbit IgG, Sc-2027, Santa Cruz 
Biotechnologies) was added to each tube. The tubes were incubated on rotating platform o/n at + 4 
°C. The next day, the beads were washed twice with PBS/BSA and re-suspended in 100 μl of 
PBS/BSA. T98G, GAMG, DKMG and NHA-empty cells were grown on 10 cm plates. After 
crosslinking, nuclei were extracted by scraping the cells to 1 ml of MNase buffer (10 mM Tris pH 7.4, 
10 mM NaCl, 5 mM MgCl2, 0.1 % NP-40, protease inhibitors) and, after 10 min incubation on ice, the 
nuclei were pelleted by centrifugation (1500 x g, 5 min, + 4 °C). The extracted nuclei were washed 
with 1 ml MNase buffer and, after centrifugation, lysed with 0.3 ml SDS lysis buffer (1 % SDS, 10 
mM EDTA, 50 mM Tris-HCl, pH 8.1, protease inhibitors). The lysates were sonicated by Bioruptor 
UCD-200 (Diagenode, Liege, y a Belgium) to result in DNA fragments of 200 to 1000 bp in length 
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and cellular debris was removed by centrifugation (full speed, 10 min, 4 °C). Sonicated chromatin 
was divided in 100 μl aliquots and suspended in 1 ml of  ChIP dilution buffer (0.01 % SDS, 1.1 % 
Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1, protease inhibitors). 2.5 ml 
BSA (100 mg/ml) was added to each tube. 100 μl chromatin sample was removed as input DNA. 
100 μl of antibody-bound beads were added to the chromatin samples and the samples were 
incubated o/n at + 4 °C on a rocking platform. The next day, the beads were washed five times with 
LiCl wash buffer (100 mM Tris pH 7.5, 500 mM LiCl, 1 % IGEPAL, 1 % Sodium deoxycholate) and 
twice with TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) and eluted with 200 μl of elution buffer 
(1 % SDS, 0.1 M NaHCO3). All samples were treated with Proteinase-K (10 mg/ml, Thermo 
Scientific) and DNA was purified with MinElute PCR Purification Kit (Qiagen). Specific primers are 
listed in Table S6. 
 
Statistical analysis 
All experiments were carried out with at least three independent replicates and One-way ANOVA 
(Tukey’s test) was used unless otherwise stated. Differences were considered statistically significant 
with a p-value < 0.05. Graphpad Prism version 5.0 was used for the analyses. Spearman´s 
correlation and correlation test of significance was computed in R to find associations between Nrf2 
activity and other features. The p-values were adjusted using the Benjamini Hochberg FDR for each 
data type tested, using the p.adjust function and BH method in R. For survival analysis the likelihood 
ratio test was used to compute the p-values. 
 
Code availability 
Code to reproduce key parts of the analysis can be obtained upon request from the authors. 
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Figure legends 
 
Figure 1. Prediction of Nrf2 overactivity using SIGNATURE and GSVA tools. A, heatmap of 
Nrf2 target gene signature expression; warm colors (red and yellow) signify high expression and 
cool colors (shades of blue), low expression. The signature model training sets consist of microarray 
samples with inactive and active Nrf2 status. The expression profile of 80 upregulated and 20 
downregulated genes relative to inactive samples are shown in rows. B, Cancer cell lines available 
from the CCLE dataset are shown ranked based on the probability of an active Nrf2 target gene 
signature. The plot shows individual samples on the X-axis and the probabilities and their confidence 
intervals on the Y-axis. Also GSVA score for independent Nrf2 target gene signature is shown beside 
the SIGNATURE tool result. Cell lines were sorted as in the SIGNATURE plot and the corresponding 
GSVA scores are shown as a heatmap. C, definition of 5 Nrf2 activity categories based on probability 
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of overactive Nrf2. D, Nrf2 hyperactive cancer types and percentage within tumor type. From the 
total of 915 samples, 66 (representing about 7 %) belong to the highest activity score (P>95 %). E, 
percentages of predicted Nrf2 overactive samples categories for Rembrandt glioma and TCGA GBM 
patient samples, separated by WHO grade are shown as a barplot. 
 
Figure 2. Validation of Nrf2 hyperactivity in glioma. A-B, Nrf2 target gene expression in TCGA 
patient samples and CCLE glioma cell lines. Samples are sorted according to Nrf2 activity from high 
activity (left) to low activity (right). Nrf2 target genes are very highly expressed in Nrf2 active H4, 
T98G, GAMG and SNU-201 cell lines (Set1), highly expressed in set2 and the expression is low in 
Nrf2 inactive cell lines (P<80 %). *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001 (Spearman´s 
correlation). C, ARE activity measured with lentiviral ARE-luciferase reporter assay. Luciferase 
activity was normalized to proteins and is depicted relative to NHA cells. n=4-8 mean ± SEM, * p < 
0.05, **p < 0.01, ***p < 0.001 (One-way ANOVA, Tukey’s test). D, Expression of validated Nrf2 target 
genes GCLM, NQO1, and HMOX1 assessed with Western blotting, using β-actin for normalization. 
E, ChIP was performed on untreated T98G, GAMG, and DKMG cells using anti-Nrf2 and normal 
rabbit IgG antibody for measuring specific and unspecific binding, respectively. RT-q-PCR was 
performed using primers specific for an ARE on NQO1 and HMOX1 gene promoters. IgG control 
values were subtracted from the output values and the binding is depicted relative to respective input 
values. Results are depicted as mean ± SEM. (n=9). ***p<0.001, (One-way ANOVA, Tukey’s test). 
 
Figure 3. Expression imbalance of NFE2L2 and KEAP1 is correlated to Nrf2 activity. A, 
NFE2L2 and Keap1 gene expression imbalance in Nrf2 active compared to Nrf2 inactive samples 
from TCGA. TCGA samples with low Nrf2 activity correlate with copy number gains in KEAP1. Copy 
number gain and loss have per gene value of 0.3 to 0.7 or -0.3 to -0.7 respectively. Red star for copy 
number variation, black for gene expression, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
(Spearman’s correlation). B, Heatmap of NFE2L2 and KEAP1 expression in CCLE glioma cell lines 
reveal amplification in NFE2L2 T98G and deletion in H4 cells. C-D, Validation of NFE2L2 and KEAP1 
gene expression in CCLE cell lines. Relative expression of NFE2L2 and KEAP1 measured with 
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qPCR. n=3, mean ± SEM, * p < 0.05, ** p < 0.01, ***p < 0.001 (One-way ANOVA, Tukey’s test). E-
F, Nrf2, Keap1 and β-actin protein levels of glioma cell lines assessed with Western blotting. DKMG 
and NHA were used as controls of normal Nrf2 expression, and A549 lung cancer cells with known 
Nrf2 hyperactivity were used as positive control. 
 
Figure 4. Autophagy dysregulation and p62 protein-protein interactions with Keap1 is linked 
to Nrf2 overactivation. A, composite pathway analysis in TCGA, CCLE and HGCC links Nrf2 
activity with several tumorigenic processes. Ranking from highest to lowest enriched processes was 
computed as mean normalized enrichment score. Each process consists of several individual 
pathways, as shown in Table S2. B, Autophagy flux measurement of LC3B and β-actin examined 
with Western blotting. Flux is impaired in GAMG cell line. C, TEM analysis of H4, T98G, GAMG, 
LN18 and NHA cells. Autophagosomal structures (black arrows), autolysosomal structures (white 
arrows) and autophagosomal-like structures (grey arrows) are indicated in the picture. 
 
Figure 5. p62 is overexpressed in samples with high Nrf2 activity and binds to Keap1 in 
glioma cell lines. A, p62 and β-actin assessed with Western blotting. B, Relative expression of 
SQSTM1 measured with qPCR. Data is depicted relative to NHA control cells. Mean ± SEM (n=3). 
*p < 0.05, **p < 0.01, ***p < 0.001. C, D, SQSTM1 mRNA (C) and p62 protein (D) are overexpressed 
in Nrf2 active TCGA samples. E, Correlation coefficient between SQSTM1 and p62 expression to 
Nrf2 activity is shown as a heatmap across diseases using TCGA data. ***p < 0.001 and Rho>0.25 
for both SQSTM1 and p62 (Spearman’s correlation). F, Heatmap of SQSTM1 gene expression and 
gene copy number aberrations in CCLE cell lines. Copy number gain and loss have per gene value 
of 0.3 to 0.7 or -0.3 to -0.7 respectively. Amplifications and deletions have values of over 0.7 or below 
-0.7. Red star for copy number variation, black for gene expression, *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001 (Spearman´s correlation). G, T98G, GAMG and A172 cell lysates were 
immunoprecipitated with p62 or Keap1 antibody, and the amount of bound Keap1 or p62 was 
detected with Western blotting. Total amount of p62 and Keap1 was also analyzed (input). H, p62, 
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phospho-p62 (Ser-351) phospho-p62 (Ser-403) and β-actin Western blotting of glioma cell lines. I, 
immunofluorescence staining of p62, Keap1 and nucleus (DAPI) in T98G cells. 
      
Figure 6. Nrf2 and p62 jointly contribute to mesenchymal transition in mesenchymal subtype 
of glioma. A, GBM subtype classification is shown for each patient sample in TCGA. Also GSVA 
scores are shown for mesenchymal and classical subtype gene sets. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001 (Spearman´s correlation).  B. Correlation coefficient between EMT gene sets 
and Nrf2 activity is shown as a heatmap across diseases using TCGA data. Significance of 
correlation is shown as stars for EMT Hallmarks MsigDB gene set, as in A. As a confirmation, 
mesenchymal signature gene set from Rokavec et. al.53 is shown. C, Western blot analysis of 
mesenchymal markers beta-catenin, snail, slug and vimentin in T98G and GAMG cells with Nrf2 and 
p62 siRNA knockdown. Beta-actin and Lamin-B1 were used as the loading control. Quantitative 
analysis of the western blot showed that both Nrf2 and p62 siRNA knockdown have significantly 
reduced the protein expression of mesenchymal markers. n=4, mean ± S.E.M. *p < 0.05, **p < 0.01, 
(One-way ANOVA Tukey’s test). D, ChIP was performed on untreated T98G, GAMG and DKMG 
cells using anti-Nrf2 and normal rabbit IgG antibody for measuring specific and unspecific binding, 
respectively. RT-q-PCR was performed using primers specific for an ARE on SNAI2 and CTNNB1 
gene enhancers. IgG control values were subtracted from the output values and the binding is 
depicted relative to respective input values. n=9, mean ± S.E.M, *p < 0.05, ***p < 0.001 (One-way 
ANOVA, Tukey’s test).  
      
Figure 7. Nrf2 and p62 jointly contribute to proliferation, disease progression and invasion. 
A, Kaplan-Meyer plot indicate that samples with highest Nrf2 activity significantly increase the risk 
of disease progression. n=22, p-value 0.0022 (Likelihood ratio test). B, Cell proliferation is decreased 
with Nrf2 and p62 siRNA knockdown. GAMG and T98G cell proliferation after Nrf2 and p62 
knockdown with siRNAs was assessed from 24-96 h growth curves. Quantification of results showed 
that cell proliferation in both the cell lines was significantly decreased. n=4, Mean ± S.E.M, *p < 0.05 
(One-way ANOVA, Tukey’s test). C, T98G cell invasion in type I collagen-cultrex matrix with Nrf2 
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and p62 siRNAs and quantification of results showed that Nrf2 and p62 siRNA knockdown 
significantly inhibits cell invasion in a 3D matrix environment. Scale bar = 100 µm; blue = nuclei, red 
= actin staining. n=3, mean ± S.E.M, *p < 0.05, ***p < 0.001 (One-way ANOVA, Tukey’s test). D, 
Anchorage-independent growth of T98G cells was inhibited with Nrf2 and p62 siRNA knockdown. 
T98G (2500 cells/well) were grown in 96-well ultra-low attachment plates in serum-free growth 
medium and the diameter of 3D growth spheres was measured at day 7. Results showed that Nrf2 
and p62 siRNA knockdown significantly decreased the anchorage-independent growth of T98G cell 
line. n=3, scale bar = 100 µm. Quantification of growth area of 3-dimensional spheres in T98G cells 
with Nrf2 and p62 siRNA knockdown. n=5, mean ± S.E.M, *p < 0.05, **p < 0.01, (One-way ANOVA 
Tukey’s test). E, schematic illustration of Nrf2 hyperactivity mechanisms and downstream effects in 
glioma. Nrf2 and p62 form a positive feedback loop in glioma, where p62 binds to Keap1 and 
promotes Keap1 degradation. p62 mediated degradation of Keap1 is further enhanced by Ser-Thr 
mediated phosphorylation of p62 and autophagy pathway. Nrf2 and p62 jointly contribute to 
mesenchymal transition, proliferation and invasion in glioma. 
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A
 Process
 # Significant 
Pathways*
 
 Rank
5 1
4 2
22 3
12 4
5 5
28 6
37 7
13 8
4 9
2 10
4 11
15 12
5 13
19 14
4 15
4 16
6 17
* FDR q-value < 0.05 in CCLE GBM, TCGA GBM and HGCC GBM
Table 1  Joined Gene Set Analysis of GBM Patient and 
Cell lines link several processes with Nrf2 activity
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